Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1994-01-10
1997-03-04
Levy, Neil
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514 49, A61K 31195, A61K 3170
Patent
active
056079745
ABSTRACT:
Patients suffering from a pathological condition resulting in reduced intracellular cysteine levels are treated with a cysteine source capable of being transported to the cellular cytoplasm. Particularly, N-acetyl cysteine is employed in the treatment of AIDS patients.
REFERENCES:
patent: 4148885 (1979-04-01), Renoux
patent: 4335210 (1982-06-01), Meister et al.
patent: 4434158 (1984-02-01), Meister et al.
patent: 4438124 (1984-03-01), Meister et al.
patent: 4440788 (1984-04-01), Tgrayama et al.
patent: 4647571 (1987-03-01), Meister et al.
patent: 4665082 (1987-05-01), Meister et al.
patent: 4710489 (1987-12-01), Meister
patent: 4744989 (1988-05-01), Payne et al.
patent: 4758551 (1988-07-01), Meister et al.
patent: 4772471 (1988-09-01), Vanlerberghe et al.
patent: 4784685 (1988-11-01), Meister
patent: 4789633 (1988-12-01), Huang et al.
patent: 4879370 (1989-11-01), Meister
Super Nutrition by Richard Passwater, 1976 pp. 154, 155 Gulfwestern Pocket Books, NY. NY.
Human Nutrition Burton et al. 4th Ed. 1988 McGraw Hill pp. 50-53, 60-62.
Droge et al. Biol. Chem. Hoppe-Seyler 369:143-148-1988.
Miester et al. Seminars in Oncology, vol. 10/1/supp. 1 Mar. 1983.
West et al.: Textbook of Biochemistry Fourth Edition. pp. 1143-1147; 1243-1250.
Kinter et al, Trans. Assoc. Am. Physicians, vol. 105, p. 36 (1992).
Eylar et al, International Immunology, vol. 5, pp. 97-101 (1993).
Dr oge, et al. "Abnormal Amino-Acid Concentrations in the Blood of Patients with Acquired Immunodeficiency Syndrome (AIDS) May Contribute to the Immunological Defect", Biol. Chem. Hoppe-Seyler (1988) 369:143-148.
Miller and Rumack "Clinical Safety of High Oral Doses of Acetylcysteine" Seminars in Ocology (1983, Suppl. 1, Mar.) vol. 10.
Ohmori and Yamamoto, "Mechanism of Augmentation of the Antibody Response in vitro by 2-Mercaptoethanol in Murine Lymphocytes", J. Exp. Med. (1982) 155:1277-1290.
Ishii T, Sugita Y, Bannai S. Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine. J Cell Physiol 133:330-336, 1987.
Eck H, Gmunder H, Hartmann M, Petzoldt D, Daniel V, Droge W. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol Chem Hoppe-Seyler 370: 101-108, 1989.
Eck H, Droge W. Influence of the extracellular glutamate concentration on the intracellular cyst(e)ine concentration in macrophages and on the capacity to release cysteine. Biol Chem Hoppe-Seyler 370: 109-113, 1989.
Fidelus R K, Tsan M. Enhancement of intracellular glutathione promotes lymphocyte activation by mitogen. Cell Immunol 97: 155-163, 1986.
Kosower E M, Kosower N S. Lest I forget thee, glutathione. Nature 224: 117-120, 1969.
Ketterer B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutation Res 202: 343-361, 1988.
Ziegler D M. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Annu Rev Biochem 54: 305-329, 1985.
Orrenius S, Jewell S A, Bellomo G, et al. Regulation of calcium compartmentation in the hepatocyte--a critical role of glutathione. In "Functions of Glutathione": Raven Press. New York. pp. 261-271. 1983.
Martensson J, Meister J. Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. Proc Natl Acad Science USA 86: 471-475, 1989.
Droge W, Pottmeyer-Gerber C, Schmidt H, Nick S. Glutathione augments the activation of cytotoxic T lymphocytes in vivo. Immunobiol 172: 151-156, 1986.
Ristow S S, Starkey J R, Stanford D R, et al. Cell surface thiols, but not intracellular glutathione, are essential for cytolysis by a cloned murine natural killer cell line. Immunol Invest 14: 401-414, 1985.
Bannai S, Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol 89: 1-8, 1986.
Meister A, Anderson M E, Hwang O. Intracellular cysteine and glutathione delivery systems. J Am Coll Nutr 5: 137-151, 1986.
Richman D D, Andrews J, and AZT Collaborative Working Group. Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. Am J Med 85 (suppl 2A): 208-213, 1988.
Moldeus P, Cotgreave I A, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 50(Suppl 1): 31-42, 1986.
Ziment I, Acetylcysteine: A Drug with an Interesting Past and a Fascinating Future, Respiration 50(Suppl 1) 26-30 (1986).
Yunis A, DNA Damage Induced by Chloramphenicol and Nitroso-Chloramphenicol: Protection by N-Acetylcysteine Respiration 50(Suppl 1) pp. 50-55 (1986).
DeJong et al. Jour of Immunological Methods, 68 (1984) 55-60.
Dr oge Wulf
Herzenberg Leonard A.
Herzenberg Leonore A.
Deutsches Krebsforschungszentrum
Levy Neil
Rowland Bertram I.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Treatment of diseases associated with cysteine deficiency does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of diseases associated with cysteine deficiency, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diseases associated with cysteine deficiency will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2146309